Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Core Viewpoint - Cocrystal Pharma, Inc. is advancing its antiviral product pipeline, particularly focusing on CDI-988 for norovirus and CC-42344 for influenza, while reporting improved financial results for the second quarter and first half of 2025 [1][17][19]. Antiviral Product Pipeline Overview - CDI-988 is being prepared for a Phase 1b norovirus challenge study, showing favorable safety and tolerability results from previous studies [2][7]. - The company utilizes a proprietary structure-based drug discovery platform to develop broad-spectrum antivirals that target conserved regions of viral enzymes, enhancing efficacy against mutations [4]. - Norovirus presents a significant market opportunity with 685 million global cases annually and a $60 billion economic impact, highlighting the unmet need for effective treatments [4][12]. Influenza Programs - Influenza poses a major health threat with approximately 1 billion cases globally each year, leading to significant morbidity and mortality [6]. - Cocrystal's CC-42344 has demonstrated in vitro activity against various influenza A strains, including those resistant to existing antivirals [8][10]. Financial Results - For Q2 2025, R&D expenses were $1.1 million, down from $4.3 million in Q2 2024, while G&A expenses decreased to $1.0 million from $1.1 million [17]. - The net loss for Q2 2025 was $2.1 million, or $0.20 per share, compared to a net loss of $5.3 million, or $0.53 per share in Q2 2024 [18]. - For the first half of 2025, R&D expenses totaled $2.5 million, down from $7.3 million in the same period of 2024, with a net loss of $4.4 million, or $0.43 per share [19]. Cash Position - As of June 30, 2025, Cocrystal reported unrestricted cash of $4.8 million, a decrease from $9.9 million at the end of 2024 [20].